Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries.
Both endothelin-A (ETA) and endothelin-B (ETB) receptors are known to be present in human coronary arteries. However, their absolute and relative amounts, functional roles, and the influence of pathology are uncertain. The goal of the present study was to characterize endothelin receptors mediating constriction in human coronary arteries and to assess the influence of cardiomyopathy (CMP) and coronary artery disease (CAD) on ET receptors in human tissue. For comparison, porcine coronary arteries were evaluated in parallel. Competition binding experiments using [125I]ET-1 and different selective and nonselective ETA- and ETB-receptor agonists or antagonists revealed similar relative densities (relative Bmax) of ETA and ETB receptors in coronary arteries from human cardiomyopathic hearts (83% ETA and 17% ETB; n = 5) and porcine hearts (78% ETA and 22% ETB; n = 5). In marked contrast, the relative Bmax of ETB receptors were significantly higher in coronary arteries from human atherosclerotic hearts (51% ETA and 49% ETB; n = 3). Total receptor density (Bmax; fmol/mg protein) was highest in porcine (385 +/- 29) arteries, followed by human CAD (253 +/- 41) and CMP (174 +/- 20) coronary arteries. The relative and absolute Bmax values for ETA and ETB receptors in coronary arteries from a donor heart were similar to those obtained in CMP hearts. There were no significant differences in affinity constants (KD) values for ET-1, ET-3, Sarafotoxin S6c (SRTX S6c), BQ-123, and bosentan (Ro 47-0203) between tissues. In human coronary arteries from CMP hearts, ET-induced constriction seemed to be solely mediated via ETA receptors. In contrast, in porcine coronary arteries 20% of the maximal effect mediated by ET-1 could be attributed to ETB receptors, in agreement with the binding data. The functional role of ETB receptors in CAD tissue could not be evaluated because of the occurrence of spontaneous phasic contractions. We conclude that ETB receptors are up-regulated in human atherosclerotic coronary arteries. Further studies are needed to determine the pathophysiological importance of these receptors.
Dagassan
P H
PH
Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Breu
V
V
Clozel
M
M
Künzli
A
A
Vogt
P
P
Turina
M
M
Kiowski
W
W
Clozel
J P
JP
D000109:Acetylcholine / Q000494:pharmacology; D000328:Adult; D000077300:Bosentan; D003324:Coronary Artery Disease / Q000378:metabolism*; D065128:Endothelin Receptor Antagonists; D006801:Humans; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000378:metabolism; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000378:metabolism*; D013449:Sulfonamides / Q000378:metabolism; D015854:Up-Regulation; D014662:Vasoconstrictor Agents / Q000378:metabolism; D014757:Viper Venoms / Q000378:metabolism
D065128:Endothelin Receptor Antagonists; D010456:Peptides, Cyclic; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D013449:Sulfonamides; D014662:Vasoconstrictor Agents; D014757:Viper Venoms; C057354:sarafotoxins s6; D000109:Acetylcholine; D000077300:Bosentan; C072247:cyclo(Trp-Asp-Pro-Val-Leu)